What's Next for Altimmune's Influenza Vaccine

Health and Healthcare

Published: March 19, 2019 9:55 am

Last Updated: December 24, 2020 9:41 am

Positive results from a midstage influenza study sent Altimmune Inc. (NASDAQ: ALT) shares sharply higher on Tuesday. Specifically, the positive data came from the firm’s Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate.

Overall, data from this study demonstrated that 100% of the evaluated subjects remained seroprotected, and the seroconversion rate was unchanged more than one year after vaccination.

As part of the study, subjects from the highest dose group were invited to return as part of a study extension to evaluate the duration of immunity one-year post-vaccination. Of 15 subjects invited, eight returned an average of 13.5 months after vaccination.

Coupled with previously demonstrated mucosal antibody and T-cell related correlates of immunoprotection, NasoVAX is well positioned to compete with other influenza vaccines currently under development.

Vipin K. Garg, Ph.D., president and CEO of Altimmune, commented:

We are excited about the continued positive NasoVAX results and believe that if approved, NasoVAX has the potential to capture a significant portion of the global flu vaccine market. Based on the continued positive data, we are seeking development and commercialization partnerships for our NasoVAX program. This will allow us to focus on our strategy of building a pipeline of multiple early to mid-stage assets. We are currently engaged in a rigorous acquisition review process focused on novel immunotherapeutic approaches for cancer, including immunostimulants and oncolytic viruses, and innovative product candidates for liver diseases. The proceeds from our recent successful financing efforts have put us in a strong position to execute our acquisition plans.

Shares of Altimmune were last seen up 31% at $3.79, with a 52-week range of $1.70 to $49.26. The stock has a consensus analyst price target of $10.00.

24/7 Wall St.
5 Sizzling Biotech Stocks Under $10 With Gigantic Upside Potential

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.